Which hedge funds own 2662247D? ITEOS THERAPEUTICS INC, Q2 2026 13F holders
0 tracked hedge funds disclosed a position in 2662247D (ITEOS THERAPEUTICS INC) in their Q2 2026 13F filings, worth $0 in total.
- 0
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 0
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 0
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $0
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $0
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $0
- Combined value Sum of the holders' reported positions in the security.
- –
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Ownership over time
Who discovered 2662247D first? Beta
| Silverarc Capital Management, LLC | Q3 2021 | +0.5 pts |
| RTW Investments, LP | Q1 2021 | +0.1 pts |
| EcoR1 Capital, LLC high conviction | Q2 2025 | +0.1 pts |
| Rubric Capital Management LP | Q3 2021 | −0.1 pts |
| RA Capital Management, L.P. | Q3 2020 | −1.7 pts |
| Octagon Capital Advisors LP | Q4 2021 | −1.9 pts |
| MPM Bioimpact LLC high conviction | Q3 2020 | −5.6 pts |
| MPM Asset Management LLC high conviction | Q3 2020 | −25.7 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.